<For the rest this abstract is, from where I stand, a disappointing one. It doesn't emphasize the big disadvantage of the Bavi arm vs the Control Arm when it comes to enrolled ECOG 2 patients. >
CP, I think you have to read this PR that just came out this morning
Quote: ECOG 2 was 13% in C and 24% in 3 mg/kg B+D arms.
Gamechanger? Given the very small size of the study, how many patients does this 11% actually represent? And interesting that we still have no resolution to the censored issue which is quite a bit more than11% Where is the updated info on this?
Cloaked you are GENIUS!!! FTM entdoc KT Thurly Geocap Jakedog r622 RRdog Goodjohn BSPalad our resident brain trust what do you men make of Cloaks rationale!!!
the real difference is the difference between other trials ecog status vs ecog comparisons between the bavi trial. the abstract did state that the condition of the patients was pretty bad.
CP, Thank you for the analysis! You amaze me! As usual, as Spock would say " it is only logical" I am looking for a surprise soon. Just a gut feeling. I am buckled in and ready to Wook it up! AtonewithPPHM
CP - that was my initial reaction as well after reading the abstract. As much as I want it to be true, do you believe these abstracts were written at some point during Q2? It was my understanding that they were submitted months ago, prior to an FDA meeting.
<However, it is the un-smoothed use of the words "and is the planned" that interests me. It is unlike Peregrine to use such clear wording. One could have expected "and is a possible or probable candidate for PIII!">